TY - JOUR
T1 - Outcome Following Mechanical Thrombectomy for Anterior Circulation Large Vessel Occlusion Stroke in the Elderly
AU - Hendrix, Philipp
AU - Killer-Oberpfalzer, Monika
AU - Broussalis, Erasmia
AU - Melamed, Itay
AU - Sharma, Vaibhav
AU - Mutzenbach, Sebastian
AU - Pikija, Slaven
AU - Collins, Malie
AU - Lieberman, Noah
AU - Hecker, Constantin
AU - Goren, Oded
AU - Zand, Ramin
AU - Schirmer, Clemens M.
AU - Trinka, Eugen
AU - Griessenauer, Christoph J.
N1 - Funding Information:
P. Hendrix, M. Killer-Oberpfalzer, E. Broussalis, I. Melamed, V. Sharma, S. Mutzenbach, S. Pikija, M. Collins, N. Lieberman, C. Hecker, O. Goren, R. Zand, C.M. Schirmer, E. Trinka, and C.J. Griessenauer declare that they have no competing interests. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. C.J. Griessenauer has acted as consultant to Stryker and Microvention and received research funding from Medtronic and Penumbra. E. Trinka reports personal fees from EVER Pharma, Marinus, Argenix, Arvelle, Medtronic, Bial-Portela & Cª, S.A., NewBridge, GL Pharma, GlaxoSmithKline, Hikma, Boehringer Ingelheim, LivaNova, Eisai, UCB, Biogen, Genzyme Sanofi, GW Pharmaceuticals, and Actavis outside the submitted work; his institution received grants from Biogen, UCB Pharma, Eisai, Red Bull, Merck, Bayer, the European Union, FWF Osterreichischer Fond zur Wissenschaftsforderung, Bundesministerium für Wissenschaft und Forschung, and Jubilaumsfond der Österreichischen Nationalbank outside the submitted work.
Publisher Copyright:
© 2021, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2022/6
Y1 - 2022/6
N2 - Background: Pooled data of randomized controlled trials investigating mechanical thrombectomy (MT) to treat anterior circulation large vessel occlusion have demonstrated safety and effectiveness across all age groups, including ≥ 80 years of age; however, only a few nonagenarians were in the ≥ 80 years subgroup. Therefore, the benefit of MT in nonagenarians is mostly unknown. Methods: Two comprehensive stroke centers retrospectively reviewed all acute ischemic stroke patients who underwent MT for anterior circulation large vessel occlusion (LVO) stroke between February 2016 and August 2020. Revascularization TICI2b/3, symptomatic intracranial hemorrhage (ICH), and functional outcome using modified Rankin scale (mRS) were assessed for cases aged < 80 years, 80–89 years, and 90–99 years. Favorable functional outcome was defined as mRS 0–2 or reaching the prestroke mRS and moderate as mRS 0–3. Results: The final data set comprised a total of 736 cases. Of these, 466 aged < 80 years, 219 aged 80–89 years, and 51 aged 90–99 years. In nonagenarians, TICI 2b/3 revascularization was observed in 84.3% while symptomatic ICH was observed in 4%. These rates were similar to 80–89 years and < 80 years age groups. Favorable and moderate functional outcome as well as death rates differed significantly between nonagenarians and < 80 years (19.6%, 29.4%, 51.0% vs 47.9%, 60.7%, 18.7%, respectively, p < 0.001), but were similar between nonagenarians and octogenarians (29.7%, 38.8%, 38.8%, p = 0.112–0.211). Conclusion: A moderate outcome among nonagenarians was observed in about 30%, while mortality rates were about 50%. Withholding mechanical thrombectomy does not appear justifiable, although the absolute treatment effect among nonagenarians remains unknown.
AB - Background: Pooled data of randomized controlled trials investigating mechanical thrombectomy (MT) to treat anterior circulation large vessel occlusion have demonstrated safety and effectiveness across all age groups, including ≥ 80 years of age; however, only a few nonagenarians were in the ≥ 80 years subgroup. Therefore, the benefit of MT in nonagenarians is mostly unknown. Methods: Two comprehensive stroke centers retrospectively reviewed all acute ischemic stroke patients who underwent MT for anterior circulation large vessel occlusion (LVO) stroke between February 2016 and August 2020. Revascularization TICI2b/3, symptomatic intracranial hemorrhage (ICH), and functional outcome using modified Rankin scale (mRS) were assessed for cases aged < 80 years, 80–89 years, and 90–99 years. Favorable functional outcome was defined as mRS 0–2 or reaching the prestroke mRS and moderate as mRS 0–3. Results: The final data set comprised a total of 736 cases. Of these, 466 aged < 80 years, 219 aged 80–89 years, and 51 aged 90–99 years. In nonagenarians, TICI 2b/3 revascularization was observed in 84.3% while symptomatic ICH was observed in 4%. These rates were similar to 80–89 years and < 80 years age groups. Favorable and moderate functional outcome as well as death rates differed significantly between nonagenarians and < 80 years (19.6%, 29.4%, 51.0% vs 47.9%, 60.7%, 18.7%, respectively, p < 0.001), but were similar between nonagenarians and octogenarians (29.7%, 38.8%, 38.8%, p = 0.112–0.211). Conclusion: A moderate outcome among nonagenarians was observed in about 30%, while mortality rates were about 50%. Withholding mechanical thrombectomy does not appear justifiable, although the absolute treatment effect among nonagenarians remains unknown.
UR - http://www.scopus.com/inward/record.url?scp=85111532422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111532422&partnerID=8YFLogxK
U2 - 10.1007/s00062-021-01063-9
DO - 10.1007/s00062-021-01063-9
M3 - Article
C2 - 34313798
AN - SCOPUS:85111532422
SN - 1869-1439
VL - 32
SP - 369
EP - 374
JO - Clinical Neuroradiology
JF - Clinical Neuroradiology
IS - 2
ER -